Determining the value of drug development candidates and technology platforms

Authors

  • Kerstin M Bode-Greuel
  • Joachim M Greuel

DOI:

https://doi.org/10.5912/jcb113

Keywords:

valuation, drug development, technology platforms, real options

Abstract

This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.

Downloads

Issue

Vol. 11 No. 2 (2005)

Section

Article